Lunelax 3.3 g/ dose Norvēģija - norvēģu - Statens legemiddelverk

lunelax 3.3 g/ dose

mylan healthcare norge as - ispaghulafrøskall - pulver - 3.3 g/ dose

Nozinan 25 mg Norvēģija - norvēģu - Statens legemiddelverk

nozinan 25 mg

mylan healthcare norge as - levomepromazinhydroklorid - tablett, drasjert - 25 mg

Nozinan 100 mg Norvēģija - norvēģu - Statens legemiddelverk

nozinan 100 mg

mylan healthcare norge as - levomepromazinhydroklorid - tablett, drasjert - 100 mg

Selukos 25 mg/ ml Norvēģija - norvēģu - Statens legemiddelverk

selukos 25 mg/ ml

mylan healthcare norge as - selendisulfid - sjampo - 25 mg/ ml

Femke 30 mg Norvēģija - norvēģu - Statens legemiddelverk

femke 30 mg

mylan ab - ulipristalacetat - tablett, filmdrasjert - 30 mg

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotic agents - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Tobi Podhaler Eiropas Savienība - norvēģu - EMA (European Medicines Agency)

tobi podhaler

viatris healthcare limited - tobramycin - cystic fibrosis; respiratory tract infections - antibakterielle midler for systemisk bruk, - tobi podhaler er angitt for undertrykkende behandling av kroniske lunge infeksjoner forårsaket av pseudomonas aeruginosa i voksne og barn i alderen 6 år og eldre med cystisk fibrose. se avsnitt 4. 4 og 5. 1 om data i ulike aldersgrupper. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Copemyl 40 mg/ ml Norvēģija - norvēģu - Statens legemiddelverk

copemyl 40 mg/ ml

mylan ab - glatirameracetat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 40 mg/ ml

Isoptin 120 mg Norvēģija - norvēģu - Statens legemiddelverk

isoptin 120 mg

mylan healthcare norge as - verapamilhydroklorid - tablett, filmdrasjert - 120 mg

Klacid 25 mg/ ml Norvēģija - norvēģu - Statens legemiddelverk

klacid 25 mg/ ml

mylan healthcare norge as - klaritromycin - granulat til mikstur, suspensjon - 25 mg/ ml